Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells

Molecular Pharmacology

Volumn 72, Issue 4, 2007, Pages 1045-1053

  Masuyama, Hisashi ^a,b   Nakatsukasa, Hideki ^a   Takamoto, Norio ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOCHROME P450 3A; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PREGNANE X RECEPTOR; SMALL INTERFERING RNA; XENOBIOTIC AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE; STEROID METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; P-GLYCOPROTEIN; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 34748865948     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.037937     Document Type: Article

References (36)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, and Gottesman MM (2003) Pglycoprotein: from genomics to mechanism. Oncogene 22:7468-7485.
2. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95:12208-12213.
3. Bhalla KN (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086.
4. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
5. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T, and Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group (2006) Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 101:158-167.
6. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, and Bonnet JD (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75:815-820.
7. de Wildt SN, Kearns GL, Leeder JS, and van den Anker JN (1999) Cytochrome P450, ontogeny and drug disposition. Clin Pharmacokinet 37:485-505.
8. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
9. Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
10. Harmsen S, Meijerman I, Beijnen JH, and Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 33:369-380.
11. Harris JW, Rahman A, Kim BR, Guengerich FP, and Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome p450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
12. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, and Callahan ASM (1995) The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387-398.
13. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702.
14. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, Mckee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
15. Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N, and Chiba K (2000) Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 6:3297-3303.
16. Lehmann JM, Mckee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023.
17. Leonard GD, Fojo T, and Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411-424.
18. Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T, and MacDonald PN (2000) Endocrine disrupting chemicals phthalic acid and nonylphenol activate pregnane X receptor-mediated transcription. Mol Endocrinol 14:421-428.
19. Masuyama H, Hiramatsu Y, Mizutani H, Inoshita H, and Kudo T (2001) The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol 172:47-56.
20. Masuyama H, Kodama J, Hiramatsu H, and Kudo T (2003) Expression and potential role of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab 88:4446-4454.
21. Masuyama H and MacDonald PN (1998) Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the Af-2 domain of VDR. J Cell Biochem 71:429-440.
22. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, and Hiramatsu Y (2005) The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 19:1170-1180.
23. Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, et al. (2007) Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer 109:957-965.
24. Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P, and Vilarem MJ (1999) Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun 260:377-381.
25. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, and Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98-106.
26. Schneider J, Efferth T, Centeno MM, Mattern J, Rodriguez-Escudero FJ, and Volm M(1993) High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 29A:554-558.
27. Schuetz EG, Brimer C, and Schuetz JD (1998) Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol 54:1113-1117.
28. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, et al. (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study. Br J Haematol 115:895-902.
29. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031-2035.
30. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369-3374.
31. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med 7:584-590.
32. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, and Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25:771-778.
33. Tsuchiya Y, Nakajima M, and Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115-124.
34. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, and Haga N (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94:15-21.
35. Wu H, Hait WN, and Yang J-M (2003) Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug resistant cancer cells. Cancer Res 63:1515-1519.
36. Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, and Yan B (1999) Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 368:14-22.